Hematologic Malignancy

Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, explored clinical data on targeting p53-mutant hematologic malignancies in the presidential symposium at the ASH Annual Meeting and Exposition.

COVID-19 remains a significant global burden, with 5 million worldwide deaths recorded as of October, according to a speaker at Chemotherapy Foundation Symposium.

A free nurse navigation service helped overcome barriers to clinical trial enrollment for patients with blood cancer, according to study results published in JCO Oncology Practice.

The Leukemia & Lymphoma Society will collaborate with three major cancer centers to provide minority and other underserved populations with greater access to blood cancer clinical trials.

Certain patients with hematologic malignancies and COVID-19 appeared at higher risk for severe infection and death, according to an analysis of data from an international registry presented at the virtual ASH Annual Meeting and Exposition.

A phase 3 trial of omidubicel has shown the graft modality superior to standard umbilical cord blood for bone marrow transplantation in patients with hematologic malignancies, according to topline data released by the agent’s manufacturer.

Patients who were treated with chimeric antigen receptor T-cell therapy had increased risk for major adverse CV events, researchers found.

An International Lymphoma Radiation Oncology Group task force has developed emergency recommendations for the management of radiation therapy for patients with hematologic malignancies during the COVID-19 pandemic.

Memorial Sloan Kettering Cancer Center announced several appointments.

Phenotype-guided dosing strategies can increase the proportion of patients with hematologic malignancies who achieve a therapeutic drug concentration of prophylactic voriconazole, according to results of two studies published in Clinical Pharmacology & Therapeutics.